CD19 and acute lymphoblastic leukemia: One study in 2022 with older adults with philadelphia negative (Ph−) ALL receiving inotuzumab ozogamicin, mini-HCVD, and/or blinatumomab consolidation (a bispecific CD19 and CD3 antibody) showed even higher CR rates (98% vs. 88%), with fewer early deaths (0–8%), and a decrease in deaths in patients with CR (5–17%).